{"product_id":"anti-hla-dr-hla-dra-antibody-picoband-monoclonal-8i10h1-bha21004291","title":"Anti-HLA-DR\/HLA-DRA Antibody Picoband® (monoclonal, 8I10H1)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eAnti-HLA-DR\/HLA-DRA Antibody Picoband® (monoclonal, 8I10H1) is an antibody reagent for detection of \u003cstrong\u003eHLA-DRA\u003c\/strong\u003e (exportin 1). Researchers commonly use anti-HLA-DRA antibodies to measure relative expression and localization across biological samples, with assay selection guided by the listed applications (WB, IHC, Flow, ELISA).\u003c\/p\u003e\u003cp\u003eBoster Bio Anti-HLA-DR\/HLA-DRA Antibody Picoband® (monoclonal, 8I10H1) catalog # M01195-3. Tested in Flow Cytometry, IHC, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e HLA-DRA (exportin 1). Alternative names: Exportin-1; Exp1; Chromosome region maintenance 1 protein homolog; XPO1; CRM1\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody format:\u003c\/strong\u003e Monoclonal; clone 8I10H1; Mouse IgG1\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies context:\u003c\/strong\u003e Host: Mouse, Reactivity: Human\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurification:\u003c\/strong\u003e Immunogen affinity purified.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunogen:\u003c\/strong\u003e E.coli-derived human HLA-DR\/HLA-DRA recombinant protein (Position: I26-L254).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight context:\u003c\/strong\u003e observed 35-37 kDa (reported)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProvided application(s):\u003c\/strong\u003e WB, IHC, Flow, ELISA\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eThese attributes help contextualize how the antibody is commonly selected (host\/clonality\/isotype\/label) and how signals are interpreted across sample types and assay formats.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eFunction:\u003c\/strong\u003e Mediates the nuclear export of cellular proteins (cargos) bearing a leucine-rich nuclear export signal (NES) and of RNAs. In the nucleus, in association with RANBP3, binds cooperatively to the NES on its target protein and to the GTPase RAN in its active GTP-bound form (Ran-GTP). Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the cargo from the export receptor. The ionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Involved in U3 snoRNA transport from Cajal bodies to nucleoli. Binds to late precursor U3 snoRNA bearing a TMG cap. Several viruses, among them HIV-1, HTLV-1 and influenza A use it to export their unspliced or incompletely spliced RNAs out of the nucleus. Interacts with, and mediates the nuclear export of HIV-1 Rev and HTLV-1 Rex proteins. Involved in HTLV-1 Rex multimerization.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCellular localization:\u003c\/strong\u003e Cytoplasm. Nucleus, nucleoplasm. Nucleus, Cajal body. Nucleus, nucleolus. Located in the nucleoplasm, Cajal bodies and nucleoli. Shuttles between the nucleus\/nucleolus and the cytoplasm.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eTissue details:\u003c\/strong\u003e Expressed in heart, brain, placenta, lung, liver, skeletal muscle, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes. Not expressed in the kidney.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eBackground:\u003c\/strong\u003e HLA class II histocompatibility antigen, DR alpha chainis aproteinthat in humans is encoded by the HLA-DRAgene. It is mapped to 6p21.32. HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCross reactivity:\u003c\/strong\u003e No cross-reactivity with other proteins.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eQuantitative and spatial profiling: expression patterns are increasingly studied across cell states using multiplex imaging and omics-informed validation.\u003c\/li\u003e \u003cli\u003eIsoforms and post-translational modifications: researchers often evaluate how isoform composition and PTMs can shift apparent molecular weight or localization.\u003c\/li\u003e \u003cli\u003eContext-aware interpretation: comparative studies commonly include perturbations (stimulation, inhibition, genetic models) to relate target changes to pathway behavior.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWestern blot (WB):\u003c\/strong\u003e compare relative target abundance and apparent size shifts (e.g., isoforms\/PTMs) across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunohistochemistry (IHC):\u003c\/strong\u003e assess distribution across tissue compartments and compare staining patterns between groups.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFlow cytometry:\u003c\/strong\u003e quantify target-positive populations and compare shifts after stimulation or differentiation.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eAcross these uses, researchers typically interpret changes in signal as relative differences between matched sample groups, considering sample preparation and biological context.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eApparent molecular weight can vary due to isoforms, proteolysis, glycosylation, phosphorylation, and sample preparation differences.\u003c\/li\u003e \u003cli\u003eSpecies reactivity and epitope conservation can influence observed signal patterns, especially in cross-species studies.\u003c\/li\u003e \u003cli\u003eControl concepts: include appropriate negative controls (e.g., isotype controls where relevant) and, when feasible, genetic or orthogonal controls (KO\/KD, peptide competition, or independent assays) to support interpretation.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eFor antibody reagents, monoclonal antibodies are often chosen for epitope consistency across lots, while polyclonals may recognize multiple epitopes and can show different background characteristics depending on context.\u003c\/p\u003e \u003c!-- Sources (internal): - UniProt entry for HLA-DRA (P01903) — UniProt Consortium — https:\/\/www.uniprot.org\/uniprotkb\/P01903 - NCBI Gene for HLA-DRA (Gene ID 3122) — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/3122 - Ensembl gene summary for HLA-DRA — Ensembl — https:\/\/www.ensembl.org - HGNC gene symbol report for HLA-DRA — HGNC — https:\/\/www.genenames.org - Antibody validation concepts (general) — NIH\/NCBI resources — https:\/\/www.ncbi.nlm.nih.gov --\u003e","brand":"Boster Bio","offers":[{"title":"100 ug\/vial \/ Unconjugated","offer_id":53068590907757,"sku":"M01195-3","price":370.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Biotin","offer_id":53068730499437,"sku":"M01195-3-Biotin","price":570.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Cy3","offer_id":53068730532205,"sku":"M01195-3-Cy3","price":570.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro488","offer_id":53068730564973,"sku":"M01195-3-Fluoro488","price":570.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro550","offer_id":53068730597741,"sku":"M01195-3-Fluoro550","price":570.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro594","offer_id":53068730630509,"sku":"M01195-3-Fluoro594","price":570.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ FITC","offer_id":53068730663277,"sku":"M01195-3-FITC","price":570.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ HRP","offer_id":53068730696045,"sku":"M01195-3-HRP","price":570.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ APC","offer_id":53068730728813,"sku":"M01195-3-APC","price":820.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ PE","offer_id":53068730761581,"sku":"M01195-3-PE","price":820.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro647","offer_id":53068730794349,"sku":"M01195-3-Fluoro647","price":670.0,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Carrier Free","offer_id":53068730827117,"sku":"M01195-3-carrier-free","price":370.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/m01195-3-hla-dr-primary-antibodies-wb-testing-1.jpg?v=1772611248","url":"https:\/\/www.ebiohippo.com\/products\/anti-hla-dr-hla-dra-antibody-picoband-monoclonal-8i10h1-bha21004291","provider":"BioHippo","version":"1.0","type":"link"}